4D Molecular Therapeutics, Inc. (FDMT) Operating margin 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) operating margin by fiscal year — reported operating income divided by reported revenue.
-187.2%FY2025 · since FY2019: -729.4% → -187.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -187.2% | +507491.1 pp |
| FY2024 | -507678.4% | -507133.7 pp |
| FY2023 | -544.6% | +2971.9 pp |
| FY2022 | -3516.5% | -3121.1 pp |
| FY2021 | -395.5% | +28.6 pp |
| FY2020 | -424.0% | +305.3 pp |
| FY2019 | -729.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net incomeFDMT Net marginFDMT Gross profitFDMT Gross marginFDMT Operating incomeFDMT Operating cash flowFDMT Free cash flowFDMT Capital expendituresFDMT Return on equityFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Total liabilitiesFDMT Shareholders’ equityFDMT overview →